Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.
Journal: JAMA dermatology
Published: May 15, 2026
How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach.
Journal: Dermatology and therapy
Published: January 27, 2026
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2.
Journal: Journal of the American Academy of Dermatology
Published: May 16, 2025
Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib.
Journal: The British journal of dermatology
Published: December 11, 2024
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2.
Journal: Journal of the American Academy of Dermatology
Published: February 21, 2024
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Journal: Dermatology and therapy
Published: January 09, 2024
Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Journal: JAMA dermatology
Published: August 09, 2023
Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.
Journal: Dermatology and therapy
Published: May 17, 2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
Journal: The British journal of dermatology
Published: May 12, 2023
Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 31, 2023
Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Journal: Clinical drug investigation
Published: December 20, 2022
Last Updated: 09/26/2026